Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis-MedSci.cn

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Ramalingam, SS; Gray, JE; Ohe, Y; Cho, BC; Vansteenkiste, J; Zhou, C; Reungwetwattana, T; Cheng, Y; Chewaskulyong, B; Shah, R; Lee, KH; Cheema, P; Tiseo, M; John, T; Lin, MC; Imamura, F; Hodge, R; Rukazenkov, Y; Soria, JC; Planchard, D

ANNALS OF ONCOLOGY, 2019; 30 (): 914

科室
- - 订阅+
  - 更多科室
工具
服务